Drug Database · Clinicians

Isoniazid + Rifampicin

Also known as: rifampin (US name, for rifampicin)

Brands (18) Duasaph-300, Duasaph-450, Fixcom 2…Show all

Antituberculosis; Combination of drugs for treatment of tuberculosis; and others PH FDA category
Fixed-dose combination.

Rx · Prescription drug28 PH productsPNF-listedPhilHealth GAMOTVAT-exempt Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Component information

No US or EU label exists for this exact combination, so information is shown for each component.

  • Use: INDICATIONS AND USAGE Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. US FDA label

  • Use: INDICATIONS AND USAGE In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the… US FDA label

Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.

Contraindications

  • Jaundice
  • Hypersensitivity to rifamycins or isoniazid
  • Saquinavir/ritonavir, lurasidone, cabotegravir, fostemsavir, lenacapavir
  • Manic or hypomanic psychosis
renalcarematters.com, reviewed

Dosing: Adult

  • Tuberculosis, continuation phase (adults): Rifampicin about 10 mg/kg (450 to 600 mg) with isoniazid about 5 mg/kg once daily, on an empty stomach
renalcarematters.com, reviewed

Dosing: Altered kidney function

Rifampicin is mainly cleared by the liver, and isoniazid by acetylation (50% to 70% of a dose appears in urine). The Irish label gives no kidney dose adjustment for the fixed combination but warns that isoniazid can cause a cerebellar syndrome, mainly in chronic kidney disease, and peripheral neuropathy. Hemodialysis removes isoniazid (advised for refractory overdose). It has no US FDA label for the combination.

Kidney function measure: The SmPC does not grade kidney impairment; bands shown on creatinine clearance (CrCl).

Show full dosing details
CrCl ≥60 mL/min
Usual: rifampicin about 10 mg/kg (450 to 600 mg) with isoniazid about 5 mg/kg once daily, 30 minutes before or 2 hours after a meal (SmPC).
CrCl 30–59 mL/min
No kidney dose adjustment stated (SmPC). Pyridoxine for patients at risk of neuropathy.
CrCl 15–29 mL/min
No dose change for isoniazid or rifampicin at CrCl <30 (ATS/CDC/IDSA 2016; MSF); the SmPC asks for careful monitoring in severe renal dysfunction. Isoniazid can cause a cerebellar syndrome, mainly in chronic kidney disease, and peripheral neuropathy (slow acetylators, malnutrition); give pyridoxine and interrupt or reduce if neurotoxicity appears (SmPC 4.4). Pyrazinamide and ethambutol (separate products or 4-drug fixed-dose tablets) need thrice-weekly dosing at CrCl <30, so 4-drug fixed-dose tablets are unsuitable in CKD G4–G5 and on dialysis.
CrCl <15 mL/min (not on dialysis)
No dose change for isoniazid or rifampicin at CrCl <30 (ATS/CDC/IDSA 2016; MSF); the SmPC asks for careful monitoring in severe renal dysfunction. Isoniazid can cause a cerebellar syndrome, mainly in chronic kidney disease, and peripheral neuropathy (slow acetylators, malnutrition); give pyridoxine and interrupt or reduce if neurotoxicity appears (SmPC 4.4). Pyrazinamide and ethambutol (separate products or 4-drug fixed-dose tablets) need thrice-weekly dosing at CrCl <30, so 4-drug fixed-dose tablets are unsuitable in CKD G4–G5 and on dialysis.
Hemodialysis (intermittent)
No dose change for either drug (ATS/CDC/IDSA 2016); give after hemodialysis on dialysis days. Add pyridoxine; watch for neuropathy and cerebellar signs (SmPC 4.4). Pyrazinamide and ethambutol (separate products or 4-drug fixed-dose tablets) need thrice-weekly dosing at CrCl <30, so 4-drug fixed-dose tablets are unsuitable in CKD G4–G5 and on dialysis.
Peritoneal dialysis
No dose change (CrCl <30 guidance; ATS/CDC/IDSA 2016, MSF); pyridoxine; watch for neuropathy and cerebellar signs.
CRRT
No data; specialist input.
  • Dialyzable? Isoniazid: yes (hemodialysis advised for refractory overdose). Rifampicin: not stated (about 80% protein-bound) (SmPC 4.9, 5.2).
  • Monitoring Liver enzymes, bilirubin, creatinine, blood count and platelets at baseline; transaminases at least monthly if over 35 years, and every 2 to 4 weeks with liver disease or alcoholism. Neuropathy and cerebellar signs (especially CKD). Purpura or thrombocytopenia: stop rifampicin. Extensive enzyme-induction interactions (SmPC 4.4, 4.5).
Children (kidney dosing)
eGFR ≥60
No pediatric dosing or kidney data in the SmPC.
eGFR 30–59
No pediatric dosing or kidney data in the SmPC.
eGFR 15–29
No pediatric dosing or kidney data in the SmPC.
eGFR <15 (not on dialysis)
No pediatric dosing or kidney data in the SmPC.
Hemodialysis (intermittent)
No pediatric dosing or kidney data in the SmPC.
Peritoneal dialysis
No pediatric dosing or kidney data in the SmPC.
CRRT
No pediatric dosing or kidney data in the SmPC.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Source: HPRA (Ireland) product information (April 2026). This generic has no US FDA label.

Dosing: Pediatric

Approved ages
No pediatric dosing in this SmPC.
Usual dose
Not given (use single agents for weight-based pediatric dosing).

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Philippines

  • Film-coated tablet: 150 mg/75 mg, 300 mg/150 mg, 450 mg/400 mg
  • Dispersible tablet: 75 mg/50 mg
  • Tablet: 300 mg/150 mg

Registered products in the Philippines

28 products registered with the Food and Drug Administration (FDA) Philippines list Isoniazid + Rifampicin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products28
Philippine FDA-registered products for Isoniazid + Rifampicin
Package insert
2-MaxRifampicin + Isoniazid
150 mg/75 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 28’s (Box of 84’s)
RxVAT-exempt
Svizera Labs Private LimitedIndia
Diafarm Inc.Importer: Ambica International CorporationTrader: Omnicals Pharma Private Limited
DRP-8927-03
Apr 5, 2037
Bercurex-1Rifampicin + Isoniazid
150 mg/75 mg Film-Coated TabletClear PVC/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
New Myrex Laboratories, Inc.Philippines
—
DRP-8632
Jan 16, 2031
BifixRifampicin + Isoniazid
150 mg/75 mg Film-Coated TabletFlex Foil x 4's (Box of 100's)
RxVAT-exempt
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, Inc.
DR-XY28918
Jul 25, 2027
DuasaphRifampicin + Isoniazid
150 mg/ 75 mg Film-Coated TabletAlu/Red PVC Blister Pack x 4's (Box of 100's); Alu/Red PVC Blister Pack x 6's (Box of 168's); Alu/Red PVC Blister Pack x 8's (Box of 80's); Alu/Red PVC Blister Pack x 9's (Box of 252's); Alu/Red PVC Blister Pack x 10's (Box of 30's and 100's); Alu/Red PVC Blister Pack x 12's (Box of 168's); Alu/Red PVC Blister Pack x 28's (Box of 84's)
RxVAT-exempt
Sai Parenterals Ltd.India
Nelpa Lifesciences Inc.
DRP-11021
Dec 9, 2030
Duasaph-300Rifampicin + Isoniazid
300 mg/ 150 mg Film-Coated TabletAlu/Red PVC Blister Pack x 4's (Box of 100's); Alu/Red PVC Blister Pack x 6's (Box of 168's); Alu/Red PVC Blister Pack x 8's (Box of 80's); Alu/Red PVC Blister Pack x 9's (Box of 252's); Alu/Red PVC Blister Pack x 10's (Box of 30's and 100's); Alu/Red PVC Blister Pack x 12's (Box of 168's); Alu/Red PVC Blister Pack x 28's (Box of 84's)
RxVAT-exempt
Sai Parenterals Ltd.India
Nelpa Lifesciences Inc.
DRP-10933
Dec 9, 2030
Duasaph-300Rifampicin + Isoniazid
300mg/150mg Film-Coated TabletAlu/Red PVC Blister Pack x 4's (Box of 100's); Alu/Red PVC Blister Pack x 10's (Box of 100's); Alu/Red PVC Blister Pack x 28's (Box of 84's)
RxVAT-exempt
Bueno Salud Care (India) Pvt. Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-14906
Feb 7, 2029
Duasaph-450Rifampicin + Isoniazid
450 mg/400 mg Film-Coated TabletAlu/Red PVC Blister Pack x 4's and 10's (Box of x 4's and 10's (Box of 100's) Alu/Red PVC Blister Pack x 28's (Box of 84's)
RxVAT-exempt
Bueno Salud Care (India) Pvt. Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-13941
May 22, 2028
Duasaph-450Rifampicin + Isoniazid
450 mg/400 mg Film-Coated TabletAlu/Red PVC Blister Pack x 4's (Box of 100's); Alu/Red PVC Blister Pack x 10's (Box of 100's); & Alu/Red PVC Blister Pack x 28's (Box of 84's)
RxVAT-exempt
Sai Parenterals Ltd.India
Nelpa Lifesciences, Inc.
DRP-14109
Dec 11, 2030
DuomaxRifampicin + Isoniazid
150 mg/75 mg Film-Coated TabletAlu/Alu Blister Pack x 4's (Box of 80's); Alu/Alu Blister Pack x 28's (Box of 336's) for DOH TB Program; Alu/Alu Blister Pack x 28's (Box of 420's) for DOH TB Program; Alu/Alu Blister Pack x 14's (Box of 336's) for DOH TB Program
RxVAT-exempt
Lupin LimitedIndia
Multicare Pharmaceuticals Philippines, Inc.Importer: Lupin Philippines, Inc.
DRP-704-03
Oct 29, 2028
Fixcom 2Rifampicin + Isoniazid
150 mg/ 75 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 80's); Alu/Clear PVDC Blister Pack x 28's (Box of 336's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Natrapharm, Inc.
DRP-15997
Feb 10, 2030
Fixcom 2Rifampicin + Isoniazid
150 mg/75 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's Box of 80's; Alu/Clear PVDC Blister Pack x 28's Box of 336's
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Natrapharm, Inc.
DR-XY36417
Feb 10, 2030
Flamaway-2Rifampicin + Isoniazid
150 mg/75 mg Film-Coated TabletAlu/PVC-PVDC blister pack x 28's (Box of 84's and 672's)
RxVAT-exempt
Svizera Labs Private LimitedIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Omnicals Pharma Private Limited
DRP-8927-01
Mar 6, 2037
IfamsoRifampicin + Isoniazid
150 mg/75 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 28's (Box of 84's); Alu/PVC-PVDC Blister Pack x 28's (Box of 672's)
RxVAT-exempt
Svizera Labs Private LimitedIndia
Ambica International CorporationTrader: Omnicals Pharma Private Limited
DRP-8927
Jul 2, 2037
Mac RHRifampicin + Isoniazid
150 mg/75 mg Film-Coated TabletAlu/Amber-colored PVC/PE/PVDC blister pack x 28 tablets (Box of 84 tablets presented as 3 blister packs x 28 tablets) Alu/Amber-colored PVC/PE/PVDC blister pack x 28 tablets (Box of 672 tablets presented as 24 blister packs x 28 tablets)
RxVAT-exempt
Macleods Pharmaceuticals LimitedIndia
Macleods Pharmaceuticals Philippines, Inc.
DR-XY49620
Feb 4, 2031
Macox RH DTRifampicin + Isoniazid
75 mg/50 mg Dispersible TabletAlu/Alu foil strip pack x 10 tablets (box of 100 tablets presented as 10 foil strip packs x 10 tablets) Alu/Alu foil strip pack x 28 tablets (box of 84 tablets presented as 3 foil strip packs x 28 tablets)
RxVAT-exempt
Macleods Pharmaceuticals LimitedIndia
Macleods Pharmaceuticals Philippines, Inc.
DR-XY49622
Feb 4, 2031
Macox RH DTRifampicin + Isoniazid
75 mg/50 mg Dispersible TabletAlu/Alu foil strip pack x 10 tablets (box of 100 tablets presented as 10 foil strip packs x 10 tablets) Alu/Alu foil strip pack x 28 tablets (box of 84 tablets presented as 3 foil strip packs x 28 tablets)
RxVAT-exempt
Oxalis LabsIndia
Macleods Pharmaceuticals Philippines, Inc.
DR-XY49623
Feb 4, 2031
Mixtreat-2Rifampicin + Isoniazid
150 mg/75 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 28's (Box of 672's)
RxVAT-exempt
Svizera Labs Private LimitedIndia
Diafarm Inc.Importer: Ambica International CorporationTrader: Omnicals Pharma Private Limited
DRP-8927-04
Jul 2, 2037
Myrin IRifampicin + Isoniazid
150 mg/75 mg Film-Coated TabletAlu/Rigid PVC/PVDC 250/100 Blister Pack x 10’s (Box of 80's); Alu/Rigid PVC/PVDC 250/100 Blister Pack x 28’s (Box of 336 tablets); Alu/Rigid PVC/PVDC 250/100 Blister Pack x 10’s (Box of 80's) [For DOH use only]
RxVAT-exempt
ICI Pakistan LimitedPakistan
Importer: Pfizer, Inc.
DRP-6598
Feb 1, 2027
NoneRifampicin + Isoniazid
150 mg/75 mg Film-coated TabletAlu-Alu Blister Pack X 4's (Box of 80's); Alu-Alu Blister Pack x 28's for DOH TB Program (Box of 336's); Alu-Alu Blister Pack x 28's for DOH TB Program (Box of 420's); Alu-Alu Blister Pack x 14's (Box of 336's)
RxVAT-exempt
Lupin LtdIndia
UNILAB, Inc.Importer: Lupin Philippines, Inc.
DRP-704
Oct 29, 2028
NoneRifampicin + Isoniazid
150mg/75mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 80's); Alu/Clear PVDC Blister Pack x 28's (Box of 336's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Patriot Pharmaceuticals CorporationTrader: Natrapharm, Inc.
DRP-15997-01
Feb 10, 2030
Philcox DuoRifampicin + Isoniazid
150 mg/75 mg Film Coated TabletAlu/PVC Blister Pack x Pack x 10's (Box of 100's)
RxVAT-exempt
Huazhong Pharmaceutical Co., Ltd.China
Amb Hk Enterprises Inc. No.
DRP-16258
Jan 10, 2030
RimactazidRifampicin + Isoniazid
300 mg/150 mg TabletBlister Pack x 10's (Box of 120's)
RxVAT-exempt
Interphil Laboratories, Inc.Philippines
Trader: Sandoz Philippines Corporation
DRP-5098
Sep 29, 2030
RimactazidRifampicin + Isoniazid
450 mg/400 mg Film- Coated TabletBlister Pack x 10's (Box of 120's)
RxVAT-exempt
Interphil Laboratories, Inc.Philippines
Trader: Sandoz Philippines Corporation
DRP-5099
Jun 7, 2030
Surestep 2Rifampicin + Isoniazid
150 mg/75 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
—
DR-XY43750
Sep 25, 2029
TB-2Rifampicin + Isoniazid
150 mg/75 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 28’s (Box of 672's)
RxVAT-exempt
Svizera Labs Private LimitedIndia
Starpharm, Inc.Importer: Ambica International CorporationTrader: Omnicals Pharma Private Limited
DRP-8927-02
Mar 2, 2037
(no brand name)Rifampicin + Isoniazid
150mg/75mg Film-Coated TabletAlu/PVC Blister Pack by 24's x 28's (Box of 672's)
RxVAT-exempt
Concept Pharmaceuticals Ltd.India
Medethix, Inc.
DRP-17441
Dec 17, 2030
(no brand name)Rifampicin + Isoniazid
75mg/ 50mg Dispersible TabletAluminum Foil Strip x 10's (Box of 100's)
RxVAT-exempt
Macleods Pharmaceuticals LimitedIndia
S.M.H.P. Marketing & Consultancy
DR-XY48165
Jul 5, 2027
(no brand name)Rifampicin + Isoniazid
75mg/ 50mg Dispersible Tablet100 tablets packed in LDPE bag enclosed in triple laminated sachet and kept in white opaque HDPE container with screw cap
RxVAT-exempt
Macleods Pharmaceuticals LimitedIndia
S.M.H.P. Marketing & Consultancy
DR-XY48166
Jul 5, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Drug interactions

Drug or classSeverityEffectWhat to do
Saquinavir/ritonavir; lurasidone, cabotegravir, fostemsavir, lenacapavirAvoidLarge falls in exposure or hepatotoxicity.Contraindicated.
Hormonal contraceptivesAvoidContraceptive failure.Use non-hormonal contraception during and for 2 weeks after.
Cyclosporine, tacrolimus, corticosteroidsAdjust or monitorLarge falls in levels (rejection risk; adrenal crisis).Monitor levels closely; raise doses.
Warfarin, azole antifungals, phenytoin, many othersAdjust or monitorLower levels by enzyme induction (S-warfarin AUC down 74%).Monitor INR or levels; adjust.
ClopidogrelAvoidMore active metabolite; bleeding.Discouraged.
Hepatitis C direct-acting antiviralsAvoidLoss of effect.Avoid.
Paracetamol, halothaneAdjust or monitorMore hepatotoxicity.Caution; avoid halothane.
AntacidsMinorLower rifampicin absorption.Give rifampicin at least 1 hour before.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed

Adverse reactions

Common

  • Thrombocytopenia (rifampicin)
  • Gastrointestinal upset
  • Orange discoloration of body fluids

Serious

  • Hepatitis (sometimes fatal; age-related with isoniazid)
  • Peripheral neuropathy, cerebellar syndrome
  • Thrombocytopenic purpura, disseminated intravascular coagulation
  • Acute kidney injury (rifampicin)
  • Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, acute generalized exanthematous pustulosis
  • Anaphylaxis with intermittent dosing
renalcarematters.com, reviewed

Monitoring parameters

  • Liver enzymes, bilirubin, creatinine, blood count and platelets at baseline; transaminases at least monthly if over 35 years, and every 2 to 4 weeks with liver disease or alcoholism. Neuropathy and cerebellar signs (especially CKD). Purpura or thrombocytopenia: stop rifampicin. Extensive enzyme-induction interactions (SmPC 4.4, 4.5). Kidney
  • Liver tests (monthly over 35 years)
  • Blood count and platelets
  • Neuropathy signs; pyridoxine
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

Half-lifeRifampicin about 3 hours (2 to 3 hours with repeated dosing); isoniazid levels halve within about 6 hours (acetylator-dependent)
Protein bindingRifampicin about 80%
Metabolism (CYP, transporters)Rifampicin hepatic (potent inducer); isoniazid by acetylation (genetic)
Renal excretion kidneyRifampicin up to 30% in urine (half unchanged); isoniazid 50% to 70% in urine within 24 hours
Dialyzability kidneyIsoniazid yes; rifampicin not stated
renalcarematters.com, reviewed

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Isoniazid + Rifampicin 75 mg + 150 mg Tablet₱4.00–₱8.00Reference ₱6.00per tabletDPRI procurement range
50 mg isoniazid + 75 mg rifampicin dispersible fixed-dose combination tablet (pediatric)₱7.25per tabletPhilHealth GAMOT fixed fee
75 mg isoniazid + 150 mg rifampicin tablet₱8.25per tabletPhilHealth GAMOT fixed fee

PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Isoniazid + Rifampicin
PNF listingOral: 50 mg + 75 mg dispersible fixed dose combination tablet (pediatric)Restrictions: List B: in vivo bioequivalence studies required (PNF code B)
PNF listingOral: 75 mg + 150 mg tabletRestrictions: List B: in vivo bioequivalence studies required (PNF code B)
PhilHealth GAMOTYes (listed since October 13, 2026)

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Health Products Regulatory Authority (Ireland). Rifinah 300/150 mg film-coated tablets SmPC (PA0540/068/002) [HPRA (Ireland) product information, April 2026; no US FDA label]. https://assets.hpra.ie/products/Human/17972/Licence_PA0540-068-002_10042026175715.pdf
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  5. PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  6. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
  7. Sanofi-Aventis Ireland Limited. (2026). Rifinah 300/150 mg film-coated tablets (rifampicin/isoniazid) [Summary of product characteristics, licence PA0540/068/002; text revised April 2026]. Health Products Regulatory Authority (Ireland). https://assets.hpra.ie/products/Human/17972/Licence_PA0540-068-002_10042026175715.pdf
  8. Nahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brozek, J. L., Cattamanchi, A., Chaisson, L. H., Chaisson, R. E., Daley, C. L., Grzemska, M., Higashi, J. M., Ho, C. S., Hopewell, P. C., Keshavjee, S. A., Lienhardt, C., Menzies, R., Merrifield, C., Narita, M., O'Brien, R., . . . Vernon, A. (2016). Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: Treatment of drug-susceptible tuberculosis. Clinical Infectious Diseases, 63(7), e147–e195. https://doi.org/10.1093/cid/ciw376
  9. Médecins Sans Frontières. (n.d.). Tuberculosis: Practical guide for clinicians, nurses, laboratory technicians and medical auxiliaries. Appendix 12: Dose adjustments in renal insufficiency. Retrieved November 17, 2026. https://medicalguidelines.msf.org/en/viewport/TUB/english/appendix-12-dose-adjustments-in-renal-insufficiency-20324400.html

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .